Annexon (ANNX) Retained Earnings (2019 - 2026)
Annexon (ANNX) posted quarterly Retained Earnings of $1.2 billion for Q1 2026, up 1281400.0% year-over-year from N/an in Q1 2025, and up 4020731.03% quarter-over-quarter from -$29000.0 in Q4 2025.
Analysis
Annexon (ANNX) Retained Earnings (2019 - 2026) Analysis & Trends
Annexon's Retained Earnings history runs 8 years deep, the most recent figure standing at $1.2 billion for Q1 2026.
- In Q1 2026, Retained Earnings rose 1281400.0% year-over-year to $1.2 billion; the TTM figure through Mar 2026 stood at $1.2 billion (up 1281400.0% YoY), while the FY2025 annual figure was -$29000.0, up 100.0% from the prior year.
- Retained Earnings for Q1 2026 stood at $1.2 billion, up from -$29000.0 in the prior quarter.
- The five-year high for Retained Earnings was $1.2 billion in Q1 2026, with the low at -$869.1 million in Q3 2025.
- The 5-year median for Retained Earnings is -$368.8 million (2022), against an average of -$213.9 million.
- The sharpest annual moves came in 2025 and 2026: Retained Earnings plunged 914731.46% in 2025, then jumped 1281400.0% in 2026.
- Annexon's Retained Earnings stood at -$438.3 million in 2022, then slumped by 30.63% to -$572.5 million in 2023, then decreased by 24.14% to -$710.7 million in 2024, then jumped by 100.0% to -$29000.0 in 2025, then jumped by 4020731.03% to $1.2 billion in 2026.
- Business Quant data shows ANNX's Retained Earnings at $1.2 billion in Q1 2026, -$29000.0 in Q4 2025, and -$869.1 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 5.10 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -4.00 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 13.05 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -6.33 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 4.38 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Annexon | 982.93 Mn | 982.93 Mn | - | 1.20 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.20 Bn |
| Mar 31, 2026 | 1.17 Bn |
| Dec 31, 2025 | 1.13 Bn |
| Sep 30, 2025 | 1.03 Bn |
| Jun 30, 2025 | 1.01 Bn |
| Mar 31, 2025 | 1.01 Bn |
| Dec 31, 2024 | 1.00 Bn |
| Sep 30, 2024 | 993.49 Mn |
| Jun 30, 2024 | 988.35 Mn |
| Mar 31, 2024 | 860.09 Mn |
| Dec 31, 2023 | 823.03 Mn |
| Sep 30, 2023 | 701.52 Mn |
| Jun 30, 2023 | 696.97 Mn |
| Mar 31, 2023 | 691.96 Mn |
| Dec 31, 2022 | 669.78 Mn |
| Sep 30, 2022 | 664.84 Mn |
| Jun 30, 2022 | 537.27 Mn |
| Mar 31, 2022 | 532.64 Mn |
| Dec 31, 2021 | 528.37 Mn |
| Sep 30, 2021 | 523.46 Mn |